Healthcare / BiotechnologyTel Aviv
$1.80
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-901000.00 · quality 66.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$17M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-18.9%
↓Gross Margin
0.7%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-370.7%
FCF / Net income
1.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $451000.0 · net income $-1.0M · FCF $-1.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $451000.00 | $451000.00 | — | — | — |
| Net Income | $-1.0M | $-1.0M | $-1.8M | $-1.3M | $435000.00 |
| EBITDA | $-930000.00 | $-930000.00 | $-1.8M | $-1.3M | $-1.0M |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Gross Margin | 0.7% | 0.7% | — | — | — |
| Operating Margin | -481.6% | -481.6% | — | — | — |
| Net Margin | -227.7% | -227.7% | — | — | — |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | — | — | — |
| Current Ratio | 0.70 | 0.70 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.7M | $-1.7M | $-707000.00 | $-901000.00 | $-1.0M |
| Returns | |||||
| ROE | -18.9% | -18.9% | -80.3% | -33.7% | 8.2% |
| Valuation | |||||
| P/B | 233.21 | 233.21 | 9.33 | 6.00 | 10.16 |
| Growth & Yield | |||||
| EPS Growth | 0.0% | 0.0% | -50.0% | -446.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4086.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+4086.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.